GAVRETO Now approved

GAVRETO™ is a once-daily oral targeted therapy for people living with RET-positive metastatic non-small cell lung cancer (NSCLC) or advanced thyroid cancer.

RET=rearranged during transfection.

RET=rearranged during transfection.